PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.81%
Revenue growth under 50% of ACB.TO's 51.88%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
23.28%
Gross profit growth at 75-90% of ACB.TO's 27.33%. Bill Ackman would demand operational improvements to match competitor gains.
119.76%
EBIT growth similar to ACB.TO's 113.17%. Walter Schloss might infer both firms share similar operational efficiencies.
119.76%
Operating income growth above 1.5x ACB.TO's 42.58%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-0.34%
Negative net income growth while ACB.TO stands at 99.88%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
5.93%
EPS growth under 50% of ACB.TO's 101.69%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
7.76%
Diluted EPS growth under 50% of ACB.TO's 101.69%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-73.67%
Negative OCF growth while ACB.TO is at 91.58%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-24.62%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
729.33%
3Y revenue/share CAGR at 75-90% of ACB.TO's 915.34%. Bill Ackman would expect new product strategies to close the gap.
-5193.14%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-372.30%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-681.49%
Negative 3Y OCF/share CAGR while ACB.TO stands at 65.63%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
1634.96%
Net income/share CAGR above 1.5x ACB.TO's 85.40% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
2589.28%
5Y net income/share CAGR above 1.5x ACB.TO's 97.34%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
428.42%
3Y net income/share CAGR above 1.5x ACB.TO's 99.68%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
6077.40%
10Y equity/share CAGR above 1.5x ACB.TO's 3505.36%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
14361.42%
5Y equity/share CAGR 1.25-1.5x ACB.TO's 10534.18%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
589.54%
Below 50% of ACB.TO's 9109.45%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.59%
AR growth well above ACB.TO's 39.70%. Michael Burry fears inflated revenue or higher default risk in the near future.
24.96%
Inventory growth well above ACB.TO's 22.66%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
0.90%
Positive asset growth while ACB.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
2.53%
Positive BV/share change while ACB.TO is negative. John Neff sees a clear edge over a competitor losing equity.
-1.79%
We’re deleveraging while ACB.TO stands at 0.90%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
135.68%
R&D growth drastically higher vs. ACB.TO's 71.36%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
2.34%
We expand SG&A while ACB.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.